MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Johnson & Johnson hit with FDA warning letter

Johnson & Johnson hit with FDA warning letter

By

Animas Corp.’s OneTouch Ping
insulin pump

The FDA issued a warning letter to medical device giant Johnson & Johnson (NYSE:JNJ) saying that the company could face penalties including fines and injunction for failing to report incidents where its OneTouch Ping and 2020 insulin pumps may have caused death or serious injury.

In an inspection of the West Chester, Pa.-based plant, the federal watchdog agency found that J&J’s Animas Corp. never reported on 1 complaint about series patient injury and delayed reporting 2 other incidents to the FDA.

The affected patients were hospitalized with diabetic ketoacidosis – a complication caused when patients lack the insulin to break down blood sugar, high blood sugar, respiratory failure and coma, according to the letter.

Sign up to get our free newsletters delivered straight to your inbox

The watchdog agency ordered the J&J subsidiary to explain, by Jan. 20, why it kept selling pumps known to fail. The company is also required to submit a plan to ensure that its failure to notify the FDA of devices that may cause serious injury or death in patients doesn’t have a repeat performance.

Animas spokeswoman Caroline Pavis told the Huffington Post that the company failed to report the 3 patient incidents to FDA because they involved patients that weren’t using the pumps as directed.

In 1 case, the patient ignored an alarm signaling that a cap had come off the machine, preventing insulin from being pumped into the body, Pavis told the new site.

Animas’ insulin pump problems are just the latest in a string of bad regulatory publicity for the New Brunswick, N.J. based medical device giant.

Just last week, the FDA ordered Johnson & Johnson, along with 32 other companies, to take another look at complication rates associated with their vaginal mesh products.

The watchdog agency asked a total of 33 companies to conduct 3 years of safety and effectiveness trials under growing concerns after deaths and injuries linked to the products spiked in recent years.

Subsidiary DePuy Orthopaedics could cost the med-tech titan up to $1 billion in lawsuits concerning metal-on-metal hip implants that were found to shed minute metal particles into a patient’s bloodstream over time.

Lawsuits over the ASR implant have piled up across the country, accusing DePuy of manufacturing a defective product, failing to warn patients and doctors of problems with the implant and negligence in designing, manufacturing and selling the product.

In case you missed it

RSS From Medical Design & Outsourcing

  • Edwards Lifesciences misses on Q4 earnings as omicron hammers hospitals
    Edwards Lifesciences (NYSE:EW) posted fourth-quarter earnings at the end of trading today that fell short of the consensus forecast on Wall Street, but reaffirmed its outlook for 2022. The Irvine, California-based heart device company reported profits of $335.3 million — or $0.53 per diluted share — on sales of $1.33 billion for the three months… […]
  • Carbon introduces next-gen 3D printers
    Carbon today announced its next-gen M-Series 3D printers based on DLS technology. The new M3 and the M3 Max printers boast faster printing, a more straightforward print experience, expanded design space and a more consistent surface finish, according to Carbon. Carbon said a 4K light engine enables a doubling of the build area with the… […]
  • Philips launches at-home, 12-lead ECG for clinical trials
    Royal Philips (NYSE: PHG, AEX: PHIA) announced today that it is expanding its remote cardiac monitoring portfolio with a patch-based, clinical-grade ECG. The new at-home electrocardiogram monitors could reduce the need for site visits during clinical trials, according to the Dutch medtech giant. At-home ECG is a hot space: iRhythm Technologies CEO Quentin Blackford recently… […]
  • TE Connectivity beats the Street in Q1
    TE Connectivity (NYSE:TEL) posted first-quarter results today that beat the consensus forecast on Wall Street. The Schaffhausen, Switzerland–based company provides connectivity and sensor solutions for a broad range of industries, including medtech. The company reported profits of $566 million — or $1.72 per share — on sales of $3.8 billion for the fiscal quarter ended… […]
  • Element Materials Technology acquired by Temasek
    Element Materials Technology this week announced that it was acquired by Bridgepoint’s Temasek for an undisclosed amount. Singapore-based Temasek has been a majority shareholder in Element since 2019. Element expects to accelerate its growth and build stronger positions in end-markets like life sciences and connected technologies, according to the company. “The acquisition of Element by… […]
  • FDA approves Medtronic’s spinal cord stimulation for chronic pain from diabetic neuropathy
    Medtronic (NYSE:MDT) announced today the FDA approved its Intellis and Vanta neurostimulator for treating chronic pain. The approval covers the Intellis rechargeable neurostimulator and the Vanta recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy. Get the full story at our sister site, MassDevice. The post FDA approves Medtronic’s spinal cord stimulation […]
  • ‘Itty bitty’ falloposcope imaging device used inside fallopian tubes for the first time
    After years of development, University of Arizona researchers have captured their first images inside fallopian tubes with a new device that could be used to search for early signs of ovarian cancer. University of Arizona BIO5 Institute Director Jennifer Barton developed the high-resolution falloposcope, which has a diameter of only 0.8 mm. “It’s itty bitty,”… […]
  • Hantel appoints VP of business development
    Hantel recently announced that it appointed Ron Balogh as VP of business development. The Hayward, California-based medtech design and contract manufacturing company appointed Balogh on Jan. 3. He will be responsible for serving the company’s current clients and growing the company by improving communications and its presence within the industry. Get the full story on… […]
  • iRhythm plans silent AFib screening pilots, high-level hires and Zio Watch evaluations
    iRhythm Technologies (NSDQ:IRTC) has big plans for 2022 and its remote external electrocardiogram monitors as the medical device developer gears up for growth. President and CEO Quentin Blackford is looking to hire an international general manager among other roles in the coming months, he told Medical Design & Outsourcing after presenting at this month’s 2022… […]
  • Innophase announces next-gen low-power WiFi modules
    Innophase (San Diego) recently announced its next-generation Talaria Two INP1014 and INP1015 WiFi plus BLE5 modules. The new modules are 40% smaller than the previous INP1010 and INP1011 platforms. INP1014 and INP1015 can enable edge-of-network IoT devices, including medical wearables, that require low power consumption and a direct-to-cloud connection, according to the company. The platforms… […]
  • Plastics and medical devices: Changes for safety and cost
    The move toward polypropylene and polyethylene in medical devices requires new manufacturing and assembly solutions such as ultrasonic and laser welding. Didier Perret, Emerson Plastics are ubiquitous in medical applications thanks to their light weight, durability and flexibility, among other attributes. However, concern has been increasing in recent years about the possible negative effects of… […]

Leave a Reply